Product Theater


Sunday, June 3, 2018

A New Indication Approved for an Oral Prescription Treatment from Pfizer


10–10:45 a.m.

Speaker:  Dr. Stephen Hanauer
Dr. Stephen Hanauer will discuss the clinical data for a newly FDA-approved indication for an oral prescription treatment for patients.

A Proactive Management Approach to IBS‐C and CIC


11–11:45 a.m.

Speaker:  Eamonn M. Quigley, MD, MACG
IBS‐C and CIC are prevalent disorders, with burdensome symptoms and high healthcare system costs. Approximately 48 million adults in the U.S. suffer from these disorders. Come to a clinical review of a proactive treatment approach that may help your patients.

Learn about a treatment for your patients with moderate to severe ulcerative colitis (UC) who are ready to begin a biologic therapy

Takeda Pharmaceuticals International

12:15–1 p.m.

In this program, expert gastroenterologist Dr. Stephen Hanauer will discuss the mechanism of action and clinical profile of a therapeutic option for adult patients with moderate to severe UC who are ready for a biologic.

Shaping the Future of GERD Management: Updates on the TIF 2.0 Procedure with EsophyX Device

EndoGastric Solutions

1:15–2 p.m.

Faculty will present latest data and indications including concomitant hiatal hernia repair.
Barham K. Abu Dayyeh, M.D., M.P.H.
Kenneth J. Chang, M.D.
Peter G. Janu, M.D.
Lunch will be served. Sponsored by EndoGastric Solutions

Expert Insight in Short Bowel Syndrome (SBS) Management


2:15–3 p.m.

Speaker:  Ken Fujioka, MD, Director of the Nutrition and Metabolic Research Center at the Scripps Clinic in San Diego, California
Dr. Fujioka, an experienced health care professional in SBS, will discuss key considerations in treating patients with SBS:
• Understand role of IV nutrition/hydration
• Review treatment options
• Discuss updated clinical data

Monday, June 4, 2018

New Post-Marketing Information and Phase 4 Data on a Proactive Way to Treat IBS-D


10–10:45 a.m.

Speakers:  Darren Brenner, MD
Please join us in a clinical review of exciting Phase 4 data and the latest post-marketing information on a proactive treatment that may help your IBS-D patients. IBS-D is a chronic functional disorder of the GI system that affects approximately 16 million people and 40% suffers remain undiagnosed.

Advanced Colonoscopic Polypectomy: Tools, Techniques, and Tips

US Endoscopy

11–11:45 a.m.

David L. Diehl, MD, FASGE, Director of Interventional Endoscopy, Geisinger Medical Center, Danville, PA. will lead a discussion around tips, techniques and the latest tools to manage flat polyps, defects and electrosurgery applications.

IBS-D: A Closer Look at Diagnosis, Microbial Imbalance and a Short-Term Treatment Option

Salix Pharmaceuticals, Inc.

12:15–1 p.m.

Dr. Mark Pimentel, Executive Director, Medically Associated Science and Technology Program, Professor of Medicine, UCLA Geffen School of Medicine, and Associate Professor Cedars-Sinai Medical Center in Los Angeles, will provide a closer look at IBS-D – Diagnosis, Microbial Imbalance, and a Short-Term Treatment Option.

CRH Medical confirms that ancillary opportunities are imperative to withstanding GI reimbursement pressures

CRH Medical Corporation

1:15–2 p.m.

CRH offers both anesthesia partnerships and hemorrhoidal banding, offsetting reimbursement cuts in core GI businesses. Despite CMS cuts, CRH Anesthesia still provides supplemental income to your practice while raising patient satisfaction. The CRH O’Regan System® provides effective treatment of hemorrhoids with favorable margins, performed by gastroenterologists and advanced practitioners alike.

Considerations in the Management of Opioid-Induced Constipation in Adults With Chronic Non-Cancer Pain

Shionogi, Inc.

2:15–3 p.m.

Speaker:  Lawrence Schiller, M.D.
Opioid-induced constipation (OIC) isn’t just about bowel movement frequency. Come to this presentation to learn about Symproic® (naldemedine) for the treatment of OIC in adult patients with chronic non-cancer pain.

Tuesday, June 5, 2018

Biosimilars: From Analytical Characterization to Real-World Use in IBD


10–10:45 a.m.

Speaker:  Gary Fanjiang, MD, MBA, MS
The program starts by reviewing the biosimilar development pathway, emphasizing steps important for the IBD community. Clinical considerations, including surrogate biomarker endpoints and sensitive patient populations that inform IBD-relevant extrapolation, will be discussed. The program will conclude with presentation and analysis of recent real-world use of biosimilars for IBD.

The Great Debate in Barrett's Esophagus:  Continuing to rely on the Seattle Protocol vs. adding WATS3D

CDx Diagnostics

11–11:45 a.m.

Moderator: Dr. Prateek Sharma
Case presentations: Dr. Charles Lightdale and Dr. Vivek Kaul

The effectiveness of both BE screening and surveillance is severely limited by random biopsy sampling error. WATS3D has been shown in large prospective studies to quickly increase the detection of both Barrett’s and dysplasia by over 80%. Based on this data should WATS now be a component of every EGD?

The Rationale Supporting Use of Biosimilars in Appropriate Patients

Merck & Company

12:15–1 p.m.

Speaker Coming Soon
The learning objectives of this presentation are 1) appreciate the goals of biosimilars in the United States 2) Discuss how the FDA evaluates biosimilars and the concept of extrapolation 3) Understand the “totality-of-the-evidence” approach for demonstrating biosimilarity

Do You Really Know Why Your Patients are Constipated? A Mechanistic Understanding of Chronic Constipation.


1:15–2 p.m.

Dr. Kyle Staller, Director of the Gastrointestinal Motility Laboratory at Massachusetts General Hospital will present an educational review of chronic constipation, a functional bowel disorder, and its association with abnormal gut motility. He will be discussing both the underlying pathophysiological and psychological factors associated with chronic constipation requiring clinical management.

Title Coming Soon


2:15–3 p.m.

Description Coming Soon

Related Opportunities

Satellite Symposia (SS)

SS provide your organization with a unique opportunity to host educational programs before or after DDW scientific sessions.

Learn More

In-Conjunction With Meetings

ICWs are meetings and events arranged by exhibitors, third party planners, educational institutions or other non-profit organizations during DDW.

Submit Request


Reserve Your Booth

Exceed business goals by exposing your company to key decision makers in GI. The Exhibit Hall will be open June 3-5, 2018.

Learn More